Discovery of novel antitumor nitric oxide-donating b-elemene hybrids through inhibiting the PI3K/Akt pathway

A series of novel furoxan-based NO-donating b-elemene hybrids were designed and synthesized to improve the anticancer efficacy of natural b-elemene. The bioassay results indicated that all of the target compounds exhibited significantly improved antiproliferative activities against three cancer cell...

Full description

Bibliographic Details
Main Authors: Chen, Jichao, Wang, Tianyu, Xu, Shengtao, Zhang, Pengfei, Lin, Aijun, Wu, Liang, Yao, Hequan, Xie, Weijia, Zhu, Zheying, Xu, Jinyi
Format: Article
Published: Elsevier 2017
Subjects:
Online Access:https://eprints.nottingham.ac.uk/42899/
_version_ 1848796596538441728
author Chen, Jichao
Wang, Tianyu
Xu, Shengtao
Zhang, Pengfei
Lin, Aijun
Wu, Liang
Yao, Hequan
Xie, Weijia
Zhu, Zheying
Xu, Jinyi
author_facet Chen, Jichao
Wang, Tianyu
Xu, Shengtao
Zhang, Pengfei
Lin, Aijun
Wu, Liang
Yao, Hequan
Xie, Weijia
Zhu, Zheying
Xu, Jinyi
author_sort Chen, Jichao
building Nottingham Research Data Repository
collection Online Access
description A series of novel furoxan-based NO-donating b-elemene hybrids were designed and synthesized to improve the anticancer efficacy of natural b-elemene. The bioassay results indicated that all of the target compounds exhibited significantly improved antiproliferative activities against three cancer cell lines (SGC-7901, HeLa and U87) compared to parent compound b-elemene. Interestingly, these compounds displayed excellent sensitivity to U87 cells with IC50 values ranging from 173 to 2 nM. Moreover, most compounds produced high levels of NO in vitro, and the antitumor activity of 11a in U87 cells was markedly attenuated by an NO scavenger (hemoglobin or carboxy-PTIO). Further mechanism studies revealed that 11a caused the G2 phase arrest of the cell cycle and induced apoptosis of U87 cells by preventing the activation of the PI3K/Akt pathway. Moreover, 11a significantly suppressed the tumor growth in H22 liver cancer xenograft mouse model with a tumor inhibitory ratio (TIR) of 64.8%, which was superior to that of b-elemene (TIR, 49.6%) at the same dose of 60 mg/kg. Together, the remarkable biological profiles of these novel NO-donating b-elemene derivatives may make them promising candidates for the intervention of human cancers.
first_indexed 2025-11-14T19:50:30Z
format Article
id nottingham-42899
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T19:50:30Z
publishDate 2017
publisher Elsevier
recordtype eprints
repository_type Digital Repository
spelling nottingham-428992020-05-04T18:57:28Z https://eprints.nottingham.ac.uk/42899/ Discovery of novel antitumor nitric oxide-donating b-elemene hybrids through inhibiting the PI3K/Akt pathway Chen, Jichao Wang, Tianyu Xu, Shengtao Zhang, Pengfei Lin, Aijun Wu, Liang Yao, Hequan Xie, Weijia Zhu, Zheying Xu, Jinyi A series of novel furoxan-based NO-donating b-elemene hybrids were designed and synthesized to improve the anticancer efficacy of natural b-elemene. The bioassay results indicated that all of the target compounds exhibited significantly improved antiproliferative activities against three cancer cell lines (SGC-7901, HeLa and U87) compared to parent compound b-elemene. Interestingly, these compounds displayed excellent sensitivity to U87 cells with IC50 values ranging from 173 to 2 nM. Moreover, most compounds produced high levels of NO in vitro, and the antitumor activity of 11a in U87 cells was markedly attenuated by an NO scavenger (hemoglobin or carboxy-PTIO). Further mechanism studies revealed that 11a caused the G2 phase arrest of the cell cycle and induced apoptosis of U87 cells by preventing the activation of the PI3K/Akt pathway. Moreover, 11a significantly suppressed the tumor growth in H22 liver cancer xenograft mouse model with a tumor inhibitory ratio (TIR) of 64.8%, which was superior to that of b-elemene (TIR, 49.6%) at the same dose of 60 mg/kg. Together, the remarkable biological profiles of these novel NO-donating b-elemene derivatives may make them promising candidates for the intervention of human cancers. Elsevier 2017-07-28 Article PeerReviewed Chen, Jichao, Wang, Tianyu, Xu, Shengtao, Zhang, Pengfei, Lin, Aijun, Wu, Liang, Yao, Hequan, Xie, Weijia, Zhu, Zheying and Xu, Jinyi (2017) Discovery of novel antitumor nitric oxide-donating b-elemene hybrids through inhibiting the PI3K/Akt pathway. European Journal of Medicinal Chemistry, 135 . pp. 414-423. ISSN 1768-3254 β-Elemene; Furoxan; Antitumor activity; Apoptosis; PI3K/Akt pathway http://www.sciencedirect.com/science/article/pii/S0223523417303112 doi:10.1016/j.ejmech.2017.04.045 doi:10.1016/j.ejmech.2017.04.045
spellingShingle β-Elemene; Furoxan; Antitumor activity; Apoptosis; PI3K/Akt pathway
Chen, Jichao
Wang, Tianyu
Xu, Shengtao
Zhang, Pengfei
Lin, Aijun
Wu, Liang
Yao, Hequan
Xie, Weijia
Zhu, Zheying
Xu, Jinyi
Discovery of novel antitumor nitric oxide-donating b-elemene hybrids through inhibiting the PI3K/Akt pathway
title Discovery of novel antitumor nitric oxide-donating b-elemene hybrids through inhibiting the PI3K/Akt pathway
title_full Discovery of novel antitumor nitric oxide-donating b-elemene hybrids through inhibiting the PI3K/Akt pathway
title_fullStr Discovery of novel antitumor nitric oxide-donating b-elemene hybrids through inhibiting the PI3K/Akt pathway
title_full_unstemmed Discovery of novel antitumor nitric oxide-donating b-elemene hybrids through inhibiting the PI3K/Akt pathway
title_short Discovery of novel antitumor nitric oxide-donating b-elemene hybrids through inhibiting the PI3K/Akt pathway
title_sort discovery of novel antitumor nitric oxide-donating b-elemene hybrids through inhibiting the pi3k/akt pathway
topic β-Elemene; Furoxan; Antitumor activity; Apoptosis; PI3K/Akt pathway
url https://eprints.nottingham.ac.uk/42899/
https://eprints.nottingham.ac.uk/42899/
https://eprints.nottingham.ac.uk/42899/